Although the combination of chemotherapy with benmelstobart plus anlotinib showed a trend towards delayed disease progression (all HRs <1), no superiority was observed against other ICI combination therapies ( Figure 3A ).
← all excerpts
Immune checkpoint inhibitors for extensive-stage small-cell lung cancer: a network meta-analysis and cost-effectiveness analysis.
1
—
—